



## Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

Nov 11, 2021

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.

### **2021 Jefferies London Healthcare Conference**

Format: Virtual presentation and investor 1x1 meetings

The presentation will be available on-demand starting Thursday, November 18, 2021, at 8:00am GMT / 3:00am ET through Friday, November 19, 2021, at 5:00pm GMT / 12:00pm ET.

Please find a link to the presentation [here](#).

A webcast can also be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com)

### **About Foghorn Therapeutics**

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

### **Media Contact:**

Fanny Cavalié, Foghorn Therapeutics Inc.

[fcavalié@foghornrx.com](mailto:fcavalié@foghornrx.com)

Gregory Kelley, Ogilvy

[gregory.kelley@ogilvy.com](mailto:gregory.kelley@ogilvy.com)

### **Investor Relations Contact:**

Ben Strain, Foghorn Therapeutics Inc.

[bstrain@foghornrx.com](mailto:bstrain@foghornrx.com)

Hans Vitzthum, LifeSci Advisors

617-430-7578

[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)